A Diagnostics & Imaging Week

Ikonisys (New Haven, Connecticut), a developer of automated cell-based diagnostic products, reported the sale to Michigan Institute of Urology (MIU; Detroit) of its proprietary Ikoniscope robotic microscopy platform and its oncoFISH bladder application.

In conjunction with the Ikoniscope, oncoFISH bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer. Earlier this year, oncoFISH bladder became the first fully automated oncology diagnostic test to be cleared for marketing by the FDA.

“The Ikoniscope is the only high-throughput ‘plug-and-play’ system on the market, and we have found that it enables greater analytical sensitivity than any other fluorescence in situ hybridization analysis system,” said Alphonse Santino, MD, president/CEO of MIU, said, “We are dedicated to providing our patients with the most up-to-date, quality, cost-effective urologic care available.”

Ikonisys’ diagnostic products automate the time-consuming laboratory technique, fluorescence in situ hybridization, which identifies chromosome aberrations associated with various diseases. oncoFISH bladder detects aberrations for chromosomes 3, 7, 9, and 17 in cells found in urine sediment to aid in the initial diagnosis of bladder cancer in patients with blood in the urine and the subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer.